Financial Fraud in Indofarma
Monday, June 3, 2024
The BPK detected Rp371.83 billion worth of fund diversion at Indofarma. Money from a number of subsidiaries was siphoned off through problematic transactions.
AN audit by the Supreme Audit Agency (BPK) finally uncovered the rot within the management of Indofarma, a state-owned company engaged in the production of pharmaceuticals and medical equipment. At the end of 2023, state auditors conducted a special purpose audit (PDTT). During the initial audit, they found irregularities indicating criminal activities, otherwise known as fraud.
The BPK then raised the status of its audit of Indofarma and all it
...
Subscribe to continue reading.
We craft news with stories.
For the benefits of subscribing to Digital Tempo, See More